12651 High Bluff Drive
About Cirius Therapeutics
Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.
Founder: Jerry Colca
CEO: Bob Baltera
CMO: Howard Dittrich
CBO: Brian Farmer
Please click here for clinical trial information.
20 articles with Cirius Therapeutics
Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics' MSDC-0602K Showed Improved Insulin Handling
Poor insulin handling associated with negative cardiovascular outcomes Preclinical data also presented showing MSDC-0602K restored pancreatic islet insulin content when used alone or in combination with liraglutide
Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting
Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, today announced data from its recently completed 12-month Phase 2b EMMINENCE clinical trial of MSDC-0602K for the treatment of non-alcoholic steatohepatitis (NASH).
Cirius Therapeutics' Phase 2b Data of MSDC-0602K for the Treatment of NASH Accepted as a Late-Breaking Oral Presentation at The Liver Meeting
Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that results of EMMINENCE, its Phase 2b clinical trial of MSDC-0602K for the treatment of NASH, will be presented at The Liver Meeting® in a late-breaking oral presentation.
Cirius Therapeutics announced that Daniel Bloomfield M.D., will be joining Cirius' scientific advisory board.
Interim Data on Cirius Therapeutics' MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions
Cirius Therapeutics announced that results from an interim analysis of exploratory endpoints from its Phase 2b EMMINENCE trial of MSDC-0602K will be presented at the American Diabetes Association 79th Scientific Sessions.
Cirius Therapeutics announced that Andrew Knudten, M.B.A., will join the company as chief technical officer and will be responsible for advancing the company's manufacturing and supply chain operations.
Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019
Cirius Therapeutics announced today that positive results from an interim analysis of exploratory endpoints from the EMMINENCE trial, its ongoing Phase 2b clinical trial evaluating MSDC-0602K in 402 patients diagnosed with non-alcoholic steatohepatitis (NASH) with fibrosis, were presented at The International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10 to 14, 2019.
Cirius Therapeutics to Present Preclinical Data for Lead Drug Candidate in NASH at The International Liver Congress
Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that it will present preclinical data supporting the importance of the unique mechanism of action of its lead drug candidate for NASH at The International Liver Congress
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
Despite the government shutdown, at least two biotech companies, Kaleido Biosciences and Cirius Therapeutics, have filed with the U.S. Securities and Exchange Commission (SEC) for initial public offerings (IPO).
12/28/2018As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that Elaine D. Sun, M.B.A., has been appointed to the company's board of directors as an independent director.
Cirius Therapeutics today announced the presentation of two posters further describing the activity of MSDC-0602K in diet-induced models of non-alcoholic steatohepatitis (NASH).
Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis
Interim analysis showed statistically significant reductions in liver enzymes, including ALT and AST, measured from baseline at six months
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Trial includes more than 380 patients in a 12-month biopsy study of lead candidate MSDC-0602K
Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH
Late-Breaking Poster Presented at The International Liver Congress
With headquarters located in San Diego, Calif. and Kalamazoo, Mich., Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing a treatment for NASH.
Cirius Therapeutics announced today that Dennis Fenton, Ph.D., has been appointed to the company's board of directors as an independent member.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.